Autopsy report · NCT01313663
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
Cause of deathNo reason given
Life of this trial
- Ran for about 1 year 5 months before it stopped.
- 20 participants enrolled.
- Results were posted on the registry 9 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Industry
- Conditions
- Lung Cancer, Small Cell
- Interventions
- pazopanib; pemetrexed
- Participants
- 20
- Sites
- 25
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.